Biophytis S.A. Logo

Biophytis S.A.

ISIN: FR0012816825 | Ticker: ALBPS | LEI: 9695008GIE061NBGU106
Sector: Health CareSub-Industry: Biotechnology
Country: France

About Biophytis S.A.

Company Description

Biophytis SA (, founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs.

Specifically, the company is advancing two proprietary drug candidates into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.

The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and collaborates with scientists at the Institute of Myology, and the Vision Institute

Year founded


Served area



14 Avenue de l'Opéra, 75001 Paris – France

Filings & Publications

Sign up and we will give you access!

Insider Trades

Date Trading entity / Person Association Trade type Volume
22.11.23 None Other Buy EUR 79,365.99
16.12.20 None Other Sell EUR 499,000.00
16.12.20 None Other Other EUR 0.00
30.04.20 None Other Other EUR 177,342.06

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.